A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease
- 1 January 2019
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 842, 208-220
Abstract
No abstract availableKeywords
This publication has 182 references indexed in Scilit:
- Blood Dendritic Cell Frequency Declines in Idiopathic Parkinson’s Disease and Is Associated with Motor Symptom SeverityPLOS ONE, 2013
- Sporadic Alzheimer’s Disease Begins as Episodes of Brain Ischemia and Ischemically Dysregulated Alzheimer’s Disease GenesMolecular Neurobiology, 2013
- Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factorsJournal of Neuroinflammation, 2011
- Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary cultureCell Death & Disease, 2011
- Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant QuestionsNeuron, 2011
- RETRACTED: Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an Alzheimer's Disease Transgenic Mouse ModelThe American Journal of Pathology, 2011
- Astrocytes: biology and pathologyActa Neuropathologica, 2009
- Cognitive and neuroinflammatory consequences of mild repeated stress are exacerbated in aged micePsychoneuroendocrinology, 2008
- 5‐Lipoxygenase gene disruption reduces amyloid‐β pathology in a mouse model of Alzheimer's diseaseThe FASEB Journal, 2007
- The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl‐leukotrienes receptorThe EMBO Journal, 2006